Zydus Lifesciences Receives USFDA Approval for Generic Hormone Medication to Relieve Menopause Symptoms
Zydus Lifesciences, a leading pharmaceutical company, announced on Tuesday that it has received the green light from the US Food and Drug Administration (USFDA) to market its generic female hormone medication in the United States. The drug, known as Estradiol Transdermal System USP, is designed to alleviate symptoms associated with menopause.
Estradiol transdermal system has been specifically developed to help prevent postmenopausal osteoporosis, a condition that affects many women as they age. The medication will be manufactured at Zydus Lifesciences’ formulation manufacturing facility in Moraiya, located in the Indian state of Gujarat.
According to IQVIA sales data, Estradiol Transdermal System generated annual sales of USD 1.9 million in the United States, indicating a strong demand for the product in the market. With the USFDA’s approval, Zydus Lifesciences is poised to expand its customer base and offer relief to women who suffer from menopause-related symptoms.
This development is a significant milestone for Zydus Lifesciences, which has a proven track record of developing innovative pharmaceutical products that cater to the healthcare needs of patients worldwide. By obtaining approval to market its medication in the United States, the company has further cemented its position as a leader in the global pharmaceutical industry.
About Zydus Lifesciences:
Zydus Lifesciences Ltd, previously known as Cadila Healthcare Limited, is a multinational pharmaceutical corporation based in Ahmedabad, India. Its primary focus is on the production of generic medicines. In 2020, the company achieved the 100th rank in the prestigious Fortune India 500 list, a testament to its success and status as a major player in the pharmaceutical industry.
For More Latest News Click Here